In order to assess the role of VEGFR2 in our MG-induced neovascular retinopathy model, a VEGFR tyrosine kinase inhibitor PTK787 (0.5 μM) was used to evaluate its effect on MG-induced angiogenesis, from 1 to 4 dpf. This evidence concerns the gene KDR and myasthenia gravis.